Oscar Reig
Servicio de Oncología Médica OncólogoGrupo de investigación
- Genómica traslacional y terapias dirigidas en tumores sólidos Accredited researcher (R3A)
Publicaciones destacadas
-
Outcomes of systemic therapy in relapsed renal cell carcinoma (RCC) treated with adjuvant sunitinib (AS)
Autores:Referencia: Journal Of Clinical Oncology 2020. -
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer
Autores:Referencia: International Journal Of Cancer 2019. -
Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer-types.
Autores:Referencia: Annals Of Oncology 2018. -
Acute tubulointerstitial nephritis associated with atezolizumab, an anti-programmed death-ligand 1 (pd-l1) antibody therapy
Autores:Referencia: Oncoimmunology 2018. -
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Autores:Referencia: British Journal Of Cancer 2017. -
The Role of Audiometry prior to High-Dose Cisplatin in Patients with Head and Neck Cancer.
Autores:Referencia: Oncology 2017. -
Corrigendum re: TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer [Eur Urol 2016;70:709-13]
Autores:Referencia: European Urology 2017. -
Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study.
Autores:Referencia: European Respiratory Journal 2017. -
TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer
Autores:Referencia: European Urology 2016. -
Diving Into Cabazitaxel's Mode of Action: More Than a Taxane for the Treatment of Castration-Resistant Prostate Cancer Patients
Autores:Referencia: Clinical Genitourinary Cancer 2016.
Proyectos destacados
-
Perfil molecular asociado al beneficio a la inmunoterapia en pacientes con cáncer de próstata hormonosensible: Estudios traslacionales asociados al ensayo clínico PROSTRATEGY
Investigador/a principal: Oscar Reig TorrasFinanciador: Fundació Clínic per a la Recerca Biomèdica (Sede o evento); Fundación SOGUGDuración: 01/01/2022 - 31/12/2024 -
Remodelación del microambiente tumoral mediante la modulación del secretoma para mejorar la respuesta a la inmunoterapia en el carcinoma renal de células claras
Financiador: Fundació Clínic per a la Recerca Biomèdica (Sede o evento); Instituto de Salud Carlos IIIDuración: 01/01/2022 - 31/12/2024 -
Molecular and functional characterization of BAP1/PBRM1 double-mutant clear cell renal cell carcinoma.
Investigador/a principal: Oscar Reig TorrasFinanciador: UT Southwestern Medical Center (Sede o evento); Fundación SEOM / Fundación CRIS contral el càncerDuración: 01/04/2019 - 01/04/2020 -
Celular plasticity and immune profile and its relationship with therapeutic response in patients with metastatic prostate cancer.
Investigador/a principal: Jose Garcia CorbachoFinanciador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento); Instituto de Salud Carlos IIICódigo: PI18/00714Duración: 01/01/2019 - 01/01/2021 -
Exploratory study of the role of TMPRSS2-ERG expression and associated transcriptional profile in metastatic castration-sensitive prostate cancer patients treated with hormonal therapy and taxanes
Investigador/a principal: Oscar Reig TorrasFinanciador: Janssen-CilagDuración: 01/01/2018